由预防治疗供给的血管外凝血因子IX池是抵御出血的真实止血屏障
本研究在体外评估4种凝血因子IX(FIX)分子与I型及IV型胶原的结合能力,并在FIX基因敲除小鼠中按50至3000 IU/kg静脉给药。结果显示重组FIX在1000和3000 IU/kg时于肝、肌肉及膝关节检测到特异信号,而50至100 IU/kg时未检测到;血浆来源FIX在包括50 IU/kg在内的所有剂量均产生信号。连续5日每日100 IU/kg重组FIX后信号亦被检测到,提示预防治疗期间FIX可在血管外蓄积。
要点
- 血浆来源FIX在50 IU/kg即可在组织中检测到信号,重组FIX需1000至3000 IU/kg才检测到。
- 连续5日每日100 IU/kg重组FIX后组织中出现FIX信号,提示预防治疗期间血管外蓄积。
- 5日预防治疗后隐静脉出血试验中血管外促凝活性显著高于单次100 IU/kg输注后7天。
核心结论
- 在重度血友病B患者接受规律FIX预防治疗时,FIX随时间在血管外蓄积可能对凝血能力和出血保护有显著影响。
研究设计与样本
- 体外研究评估4种FIX分子(血浆来源和重组)与I型及IV型胶原的结合能力。
- 在FIX基因敲除小鼠中按50至3000 IU/kg静脉给予FIX分子。
- 采用免疫组化检测肝脏、肌肉和膝关节中的FIX信号,并用隐静脉出血试验评估血管外促凝活性。
主要发现
- 重组FIX在1000和3000 IU/kg时于肝脏、肌肉和膝关节检测到特异FIX信号,而在常用临床剂量50至100 IU/kg时未检测到。
- 血浆来源FIX在包括50 IU/kg在内的所有剂量均产生FIX信号。
- 连续5日每日100 IU/kg重组FIX后亦检测到FIX信号,提示预防治疗期间FIX可在血管外蓄积。
- 5日预防治疗后隐静脉出血试验中血管外促凝活性显著高于单次100 IU/kg输注后7天评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Factor (F)IX can bind to type IV collagen in the endothelial basement membrane and diffuse into extravascular spaces. Previous studies in rodents have reported a large biodistribution of FIX. OBJECTIVES: The aim of the study was to evaluate the potential hemostatic activity of extravascular FIX and its role in protecting against joint bleeds. METHODS: The capacity of 4 different FIX molecules (plasma-derived and recombinant) to bind type I and type IV collagen was studied here. FIX molecules were also administered intravenously at doses of 50 to 3000 IU/kg in FIX knockout mice. RESULTS: A specific FIX signal was detected in immunohistochemistry in the liver as well as in muscles and knee joints with recombinant FIX molecules injected at 1000 and 3000 IU/kg but not at the usual clinical doses of 50 to 100 IU/kg, while plasma-derived FIX generated a FIX signal at all doses, including 50 IU/kg. Such a signal was also detected after five 100 IU/kg daily infusions of recombinant FIX, suggesting that FIX can accumulate in the extravascular space during prophylaxis. The extravascular procoagulant activity of FIX, assessed in saphenous vein bleeding assays, was significantly higher in hemophilia B mice after these 5 days of prophylaxis compared to a single infusion of 100 IU/kg of FIX and assessment of FIX activity 7 days later. CONCLUSION: Taken together, these results show that in individuals with severe hemophilia B receiving regular prophylaxis with FIX, extravascular accumulation of FIX over time may have a significant impact on the coagulation capacity and protection toward bleeding.
引用
- Leuci A, Enjolras N, Marano M, et al. Extravascular factor IX pool fed by prophylaxis is a true hemostatic barrier against bleeding. J Thromb Haemost. 2023. PMID: 38072379. doi:10.1016/j.jtha.2023.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。